Search results
12 sie 2024 · Random biopsies of the urinary bladder in the absence of cystoscopic findings for patients with positive cytology or for monitoring the recurrence of nonmuscle invasive bladder cancer (Eur Urol 2003;44:47, Scand J Urol Nephrol 2010;44:11)
- Case 331
Carcinoma in situ can involve von Brunn nests, resulting in...
- Case 331
Bladder carcinoma in situ (abbreviated “CIS”) is always high grade and requires immediate treatment. Bladder CIS presents itself as a flat, rash- or moss-like growth on the bladder lining. In some cases it may not be visible upon examination and only shows up when biopsy samples are examined by a pathologist.
Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually reported within the heterogeneous context of non–muscle-invasive bladder cancer (NMIBC) but warrants special consideration. To review the contemporary literature on the diagnosis and management of CIS.
17 sie 2024 · This summary represents the updated European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), comprising Ta, T1, and carcinoma in situ (CIS). The information presented is limited to urothelial carcinoma (UC), unless otherwise specified.
15 lip 2020 · Carcinoma in situ (CIS) of the bladder is by definition a high-grade flat lesion confined to the mucosa, which is morphometrically similar to muscle-invasive bladder cancer (MIBC) [1]. CIS of the bladders displays a variable clinical behavior; the risk of muscle invasion in untreated patients is up to 80% and the disease-specific mortality may ...
Carcinoma in situ (also called CIS or Tis) means there are very early cancer cells in the inner layer of the bladder lining. The cancer cells look very abnormal and are likely to grow quickly. This is called high grade. CIS can grow in more than one place in the bladder lining. It looks like flat velvety patches through a microscope.
21 sie 2015 · Management of carcinoma in situ of the bladder remains a complex and challenging endeavor due to its high rate of recurrence and progression. Although it is typically grouped with other nonmuscle invasive bladder cancers, its higher grade and aggressiveness make it a unique clinical entity.
